Impact of tumor burden on survival in patients with recurrent or metastatic head and neck cancer treated with immune checkpoint inhibitors

Immune checkpoint inhibitors (ICIs) have become the standard treatment for recurrent or metastatic head and neck cancer (RM-HNC). However, many patients fail to benefit from the treatment. Previous studies have revealed that tumor burden predicts the efficacy of ICIs, but this association remains un...

Descripción completa

Detalles Bibliográficos
Autores principales: Matoba, Takuma, Minohara, Kiyoshi, Kawakita, Daisuke, Takano, Gaku, Oguri, Keisuke, Murashima, Akihiro, Nakai, Kazuyuki, Iwaki, Sho, Tsuge, Hiroshi, Tanaka, Nobukazu, Imaizumi, Sae, Hojo, Wataru, Matsumura, Ayano, Tsukamoto, Koji, Esaki, Shinichi, Iwasaki, Shinichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9395325/
https://www.ncbi.nlm.nih.gov/pubmed/35996017
http://dx.doi.org/10.1038/s41598-022-18611-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9395325/
https://www.ncbi.nlm.nih.gov/pubmed/35996017
http://dx.doi.org/10.1038/s41598-022-18611-z

Ejemplares similares